The EU finally is finally starting a new battle in the war against drug counterfeiting, reports Pharm Exec Europe columnist Reflector.
How will the long-threatened revision of the EU's twenty-year old legislation on animal testing affect the industry?
Reflector ponders the good, the bad and the ugly aspects of the EU's antitrust investigations.
Reflector ponders the good, the bad and the ugly aspects of the EU's anti-trust investigations.
As two more countries sign up for the euro, Reflector pierces the New Year mist in Brussels to look at just what a common currency means for European pharma.
The regulators are full of good ideas when it comes to new initiatives, but the industry knows better than to expect any real advances. Reflector reports on the EIT and the IMI, the latest proposals struggling to leave the launching pad.
The EU gives boost to advanced therapies, but deals blow to GMOs
Both pharma and the animals it tests on are keen to escape the 'cages' that constrain them. But the industry-vs-activists debate intensifies at every turn of the key, says Reflector.
...the EMEA and the European Commission have at last publicly admitted what industry has been saying for years — that Europe's clinical trials legislation is not working as designed.
